COVID-19

A new survey conducted by NCPA showed that many independents are serving vulnerable populations but are not receiving adequate supplies of COVID-19 vaccine.

Authors of a paper published in Neurology suggest that a case of Guillain-Barré Syndrome reported in a COVID-19 vaccine trial may have been a coincidence.

The CDC and FDA will further investigate the reports of blood clots following administration of the vaccine.

A recent study examined persistent symptoms following mild COVID-19 infection.

Here's the roundup of COVID-19 related news from this week.

A session at the American Pharmacists Association 2021 Annual Meeting and Exposition addressed recent immunization practice changes.

In part 2 of our interview, Rich Tremonte of AmerisourceBergen discusses distribution highlights, inspiring efforts from pharmacists, and the future of COVID-19 vaccination.

The FDA has made revisions to the emergency use authorization for the Moderna COVID-19 vaccine.

Here’s an overview of what’s in the late-stage pipeline.

Rich Tremonte from AmerisourceBergen discusses community pharmacy's integral role in the rollout of COVID-19 vaccines and highlights some inspiring stories from community pharmacists.

Here’s a roundup of the latest coronavirus-related news.

The vaccine is 91.3% effective against COVID-19 for up to 6 months after the second dose, according to an analysis of data collected through March 13.

Pfizer/BioNTech released data on their COVID-19 vaccine that indicates high efficacy in children aged 12 to 15 years.

A retrospectively analysis assessed the effect of a remote vaccination review process on vaccination status during the COVID-19 pandemic.

A team of researchers have released study results that show the Moderna and Pfizer vaccines are indeed safe and effective for this population.

Here’s a roundup of the latest coronavirus-related news.

The updated analyses of the AZD1222 COVID-19 vaccine will be submitted to the FDA for emergency use authorization, according to AstraZeneca.

A recent study looked at the role of the influenza vaccine in COVID-19 susceptibility and severity

AstraZeneca responded to the concerns by promising to release the most up-to-date data within 48 hours.

Increasing reports have surfaced of vaccine recipients experiencing delayed cutaneous side effects after receiving the first dose.

AstraZeneca is preparing to submit its COVID-19 vaccine data to the FDA for emergency use authorization in the coming weeks.

The CDC reported data demonstrating high adherence to COVID-19 vaccine doses among recipients.

Here’s a roundup of the latest coronavirus-related news.

Survey results suggest independent pharmacies may be better positioned than chains to offer COVID-19 POC testing to their patients.

Often referred to as “long COVID” patients or “long-haulers,” these patients continue to experience symptoms of illness far past the acute phase of this viral disease.